ATV-1601 Shows Promise in Phase 2 Study for Hereditary Hemorrhagic Telangiectasia
A 2-part study is underway to evaluate the efficacy of ATV-1601 in patients with moderate to severe HHT, with a randomized controlled design in Part 1.
Therapeutic Area
Therapeutic area intelligence for Hereditary Hemorrhagic Telangiectasia with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.